Struggling to lose weight? The skinny shot may be your breakthrough.
Semaglutide & Tirzepatide have been a game changers for many individuals struggling with weight loss, but they should be used carefully, under active medical supervision.
Semaglutide-"the skinny shot" it’s a GLP-1 agonist that was developed to improve blood sugar control in type2 diabetes.
In 2021 FDA approved Semaglutide for chronic weight management in adults with a BMI of 25 or more.
Numerous studies have shown that a reduction as little as 10% of the total body weight results in significant reduction of many comorbidities associated with obesity such as heart disease, diabetes, high blood pressure, osteoarthritis, cancer, and the list goes on…
The average weight loss with Semaglutide is typically in the range of 10 to 20 pounds. While this may appear to be a relatively a modest achievement, the impact in one’s daily life can be profound. The subtle shift in weight can result in noticeable improvement in overall health, energy levels and self-esteem.
Concerns & side effects with Semaglutide include:
-gastrointestinal symptoms like nausea, vomiting, diarrhea, and constipation, especially when starting the medication program.
-Pancreatitis
-Gallbladder problems, including gallstones
-Low blood sugar
-Increased heart rate
-Thyroid cancer risk has been seen in animals studies, but has not been shown in humans studies.
- ozempic face
Considerations;
-individuals with a lower BMI than 25 may not experience the same degree of weight loss or metabolic improvements from Semaglutide as those with higher BMIs.
Slowly, titrating the medication will result in better tolerance and avoidance of some of the side effects associated with it.
Semaglutide while very effective, it’s not a miracle treatment for everyone.
Medical supervision is key because of its potential side effects and contraindications such as personal or family history of thyroid cancer and multiple endocrine neoplazia syndrome.
Regular monitoring by a qualified healthcare provider is essential.
Comments